NINDS Neuroscience Funding Announcements

The National Institute of Neurological Disorders and Stroke (NINDS) is considering developing a medicinal chemistry program for therapy development. The goal of the program would be to develop lead compounds with sufficient potency, efficacy, and drug-likeness to begin the preclinical pharmacology and safety (ADMET) studies required for an investigational new drug (IND) application. The NINDS envisions awarding a contract for medicinal chemistry services.